2020 Addictions and Their Treatment Course On Demand Material (No CE)

The 2020 Addictions and Their Treatment Course took place virtually in October 2020. Each presentation was pre-recorded and offered as a on-demand lecture. Registrants were encouraged to watch all on-demand lextures prior to attending a 1-day series of live Webinar discussions and Q&A sessions. During the live component, participants had the opportunity to interact with our expert presenters, who responded to questions and comments about topics relevant to the on-demand lectures.

This enduring material course includes all on-demand lectures, a recording of each Q&A session, and access to presentation slides.

There are no continuing education credits offered with this course material.

Course Access Information

Expiration Date: December 31, 2022
Content Available Until: December 31, 2023

This activity is available to purchase for two years after the original date of release. Once the activity expires, the content will be available for learners to view for one additional year. Access to the content will then be removed to ensure content validity in all AAAP educational activities.

Target Audience

This course is meant to provide an introduction and review of addiction topics ranging from neurobiology to clinical treatment, and is intended to support efforts for board exam preparation and to enhance your clinical knowledge and skills.

This course is designed for anyone who is interested to learn more about substance use disorders and to help prepare for subspecialty certification in Addiction Psychiatry and Maintenance of Certification. It is recommended for Addiction Psychiatry and Addiction Medicine fellows, general psychiatry residents, and periodically for all academic and treatment personnel to stay updated on the most recent trends in the addiction field. Therefore, it is equally relevant to junior faculty and all clinicians as well as experienced practitioners and other health professionals.

Recent reports indicate the average primary care provider has more than 2,000 patients and as many as 200 of them could have a substance use disorder. This course provides PCPs a comprehensive review of current research and clinical applications to educate health professionals in evidence-based approaches in their clinical practices. It is relevant to faculty in primary care as well.

Course Learning Objectives

At the conclusion of this activity, participants should be able to:

Describe new advances in the pharmacotherapy and psychotherapy of addictive disorders.
Discuss the epidemiology of substance use disorders and their co-occurrence with other mental disorders and review current recommended approaches for concurrent treatment of substance use disorders and other mental health disorders
Describe the role of genetics in the risk for developing alcohol and other drug use disorders.
Identify the major neurobiological pathways involved in addictive disorders.
Identify the molecular mechanisms that are altered following drug and alcohol use.
Review the literature on screening and brief intervention effectiveness, and teach this technique so it is applied.
Review current treatment guidelines and how to utilize them in clinical practice.

Session Topics & Learning Objectives

Alcohol
Faculty: Bryon Adinoff, MD

At the conclusion of this session, participants should be able to discuss the following aspects of alcohol use disorders:
1. Historical aspects of the medical model.
2. Diagnosis
3. Drinking Guidelines
4. Epidemiology
5. Risk factors
6. Pharmacology of alcohol
7. Consequences of alcohol use on the brain
8. The treatment of alcohol withdrawal and relapse

Behavioral Addictions
Faculty:Timothy Fong, MD

At the conclusion of this session, participants should be able to:
1. State the clinical characteristics of gambling disorder and hypersexual disorder.
2. Demonstrate improvement in screening and assessment techniques for behavioral disorders.
3. Describe current treatment options.

Benzodiazepines: The Hidden Epidemic
Faculty: Richard Ries, MD

At the conclusion of this session, participants should be able to:
1. Define both therapeutic and potentially harmful uses of Benzodiazepines in medical treatment.
2. Evaluate the risks of Benzodiazepine treatment.
3. Utilize alternative agents when indicated.
4. Differentiate toxicological urine screens utilized for Benzodiazepines.

Cannabis
Faculty: Petros Levounis, MD, MA

At the conclusion of this session, participants should be able to:
1. List three intoxication symptoms and three withdrawal symptoms of cannabis.
2. Discuss potentially beneficial uses of cannabinoids.
3. Use effective psychosocial interventions to treat cannabis use disorder.
4. Explain the increased dangerousness of synthetic cannabinoids.

Co-Morbidity of Substance and other Psychiatric Disorders
Faculty: Edward Nunes, MD

At the conclusion of this seminar, participants should be able to:
1. State the DSM-5 definitions of Substance Inducted disorders, how to distinguish substance induced from independent disorders, or substance intoxication or withdrawal, and how to apply this to history-taking and diagnostic formulation.
2. Discuss the possible relationships between co-occurring substance and other mental disorders and how this informs diagnostic assessment.
3. Describe the evidence from clinical trials on treatment of depression and other co-occurring mental disorders among patients with substance use disorders.

Emerging Drugs
Faculty: Petros Levounis, MD, MA

At the conclusion of this session, participants should be able to:
1. Identify emerging drugs on-the-basis of their chemical structure.
2. Discuss the intoxication presentation of ecstasy, ketamine, and GHB.
3. List one positive and one negative effect of each of the seven major emerging drugs of abuse.

Forensic Issues in Addiction
Faculty:Laurence Westreich, MD

At the conclusion of this session, participants should be able to:
1. Recognize the interactions between the legal process and addicted individuals.
2. Describe the Landmark Supreme Court Cases in Addiction.
3. Identify common criminal and civil matters, as related to addiction.
4. Discuss the basics of the Forensic Psychiatric Evaluation and Testimony, especially as related to addiction.
5. Formulate their own knowledge base and practice in the field of forensic addiction psychiatry.

General Concepts and Epidemiology
Faculty: Kevin Sevarino, MD, PhD

At the conclusion of this session, participants should be able to:
1. Review the current working definitions of addiction.
2. Describe the basic epidemiology of substance use disorders, including rates of use or misuse of the major classes of misused substances.
3. Identify risk factors associated with development of substance use disorders.
4. Discuss general concepts of treatment for substance use disorders.

Inequities in Addiction Treatment for Racial and Ethnic Minority Populations
Faculty: Ayana Jordan, MD, PhD

At the conclusion of this session, participants should be able to:
1. Describe the social and political factors that contribute to the existence and propagation of health disparities among racial and ethnic under-represented minority (URM) communities
2. Describe culturally-informed treatment options that are being studied, which may be more acceptable to racial/ethnic URM populations
3. Identify other substances commonly used in racial/ethnic minority communities that are largely unrecognized in the media

Medical Comorbidities in Patients with Substance Use Disorders
Faculty: Steven Batki, MD

At the conclusion of this session, participants will be able to:
1. Identify the main medical morbidities caused by alcohol, opioid, stimulant and tobacco use disorders.
2. Discuss the epidemiology and basic features of HIV and HCV -- the main infectious diseases associated with injection drug use.
3. Identify the key organ systems affected by alcohol, stimulants, and tobacco use disorders.

Motivational Interviewing
Faculty: Carla Marienfeld, MD

At the conclusion of this session, participants should be able to:
1. Describe and demonstrate the spirit of motivational interviewing (MI).
2. Utilize the four processes (engaging, focusing, evoking, planning) of MI.
3. Utilize patient-centered MI skills to help elicit and strengthen the internal motivation for change.

Naloxone Overdose Training
Faculty: Michelle Lofwall, MD

At the conclusion of this session, participants should be able to:
1. Describe the pharmacology and effectiveness of IV, IM, SC and IN naloxone for overdose reversal.
2. Discuss with patients and their network supports on how to identify an opioid overdose, administer naloxone and activate EMS.

Neurobiology and Genetics
Faculty: Kevin Sevarino, MD, PhD

At the conclusion of this session, participants should be able to:
1. Recognize animal models of addiction when encountered in the literature.
2. Describe the basic neurocircuitry and neurochemistry of substance use disorders.
3. Identify basic approaches to studying the genetics of addiction.
4. Discuss epigenetic mechanisms implicated in addiction.

Pain and Addiction
Faculty: Roger Chou, MD

At the conclusion of this session, participants should be able to:
1. Review Historical Information: Context for the current epidemic of opioid misuse in the U.S.
2. Describe the approach to the assessment and managing acute pain in high-risk patients.
3. Identify the role of buprenorphine in treating pain and opioid use disorder.

Pregnancy and Substance Use Disorders
Faculty: Michelle Lofwall, MD

At the conclusion of this session, participants should be able to:
1. Describe the challenges in treating substance use disorder during pregnancy.
2. Describe the comorbid conditions that may affect the health of mother and child.
3. Describe information on treatment with a focus on Opioid Use Disorder.

Psychosocial Treatment of the Addictions
Faculty: Edward Nunes, MD

At the conclusion of this session, participants should be able to:
1. List evidence-based behavioral treatments for substance use disorders.
2. Describe the general principles and techniques involved in each of the behavioral treatments covered.
3. Discuss the empirical evidence supporting the effectiveness of the behavioral treatments for substance use disorder.
4. Describe the principles behind combining medications with behavioral therapies for treating substance use disorders, and list several combinations that have been studied.

Review of Opioids and Treatment of Opioid Use Disorders
Faculty: John Renner Jr., MD

At the conclusion of this session, participants should be able to:
1. Describe the epidemiology and neurobiology of opioid dependence.
2. Describe the type of opioids and their effects.
3. Describe the pharmacology of opioids.
4. Describe the various treatment modalities for opioid dependence.
5. Assess the treatment needs of pain patients and adolescents.

Sex and Drugs: Gender Differences in Substance Use Disorders
Faculty: Kathleen Brady, MD, PhD

At the conclusion of this presentation, participants should be able to:
1. Summarize prevalence of categories that influence SUDs for both genders.
2. Describe the etiologic factors that influence SUDs among females and males.
3. Compare the comorbidity differences between genders.
4. Discuss the relationship between trauma and SUDs and how this relationship is impacted by gender.
5. State the biologic influences of SUDs in both genders.
6. Discuss gender-specific treatment implications.

Stimulant-Related Disorders
Faculty: Steven Batki, MD

At the conclusion of this seminar, participants should be able to:
1. Identify the main neurochemical effects of stimulants on brain monoamines.
2. Recognize the main physical and behavioral effects of acute cocaine and methamphetamine intoxication and withdrawal.
3. Identify the chief medical and psychiatric sequelae of chronic cocaine or methamphetamine use disorder.
4. Identify 3 medications that have been tested in the treatment of cocaine or methamphetamine use disorder.

Substance Use Disorder Treatment in Hospital Settings
Faculty: Sanchit Marut, MD, MS

At the conclusion of this session, participants should be able to:
1. Recognize how SUDs are diagnosed
2. Discuss common hospital presentations of patients w/SUDs
3. Describe strategies for assessing substance use with hospitalized patients
4. Compare priorities of hospital care for:
a. Alcohol: SBIRT, managing withdrawal, starting pharmacotherapy
b. Nicotine: managing withdrawal, enhancing motivation
c. Opioids: pain management, starting/continuing MAT
5. Discuss effective responses to treatment-interfering behaviors
6. Describe steps to help patients with SUDs access ongoing treatment

Substance Use Disorders in the Older Population
Faculty: Louis Trevisan, MD

At the conclusion of this session, participants should be able to:
1. Summarize the prevalence of substance use disorders in older Americans.
2. Identify the signs and symptoms of an older person with a substance use disorder.
3. Describe evidenced based treatments for the older person with a substance use disorder.

Suicide and Substance Use Disorders
Faculty: Richard Ries, MD

At the conclusion of this session, participants should be able to:
1. Differentiate key factors more associated with suicide vs overdose.
2. Perform risk assessment for both suicide and overdose to improve patient care.
3. Translate information from study evidence around both suicide and overdose into their daily clinical interviews and care planning.

Tobacco
Faculty: Jill Williams, MD

At the conclusion of this session, participants should be able to:
1. Recognize trends in current tobacco use.
2. Describe the addicting effects of tobacco and it’s impact on health.
3. Describe pharmacologic and non-pharmacologic treatment options.
4. Discuss new products including e-cigarettes

Urine Drug Testing
Faculty: Kevin Sevarino, MD, PhD

At the conclusion of this presentation, participants should be able to:
1. Discuss clinical issues in performing urine drug testing (UDT).
2. Describe the basic types of UDT and when they should be used.
3. Define the metabolism of opioids and benzodiazepines in order to interpret UDT results.
4. Describe the basic functions of a medical review officer and what a chain of custody entails.

Youth with Substance Use Disorders and Attention Deficit Hyperactivity Disorder
Faculty: Amy Yule, MD

At the conclusion of this seminar, participants should be able to:
1. Describe how developmental differences impact the assessment and treatment of youth with Substance Use Disorders (SUD).
2. Assess Attention Deficit Hyperactivity Disorder (ADHD) in the context of a SUD.
3. Treat ADHD when co-occurring with SUD.

Faculty

Sanchit Maruti - Director and Speaker

MD, MS

University of Vermont Medical Center

Dr. Sanchit Maruti, MD, MS, is the Medical Director of the UVM Medical Center (UVMMC), Addiction Treatment Program, and an Attending Psychiatrist on the In-patient Psychiatry Service at UVMMC. He is also an Assistant Professor of Psychiatry at the Larner College of Medicine at the University of Vermont.
Dr. Maruti received his MD degree from the University of Vermont College of Medicine where he was awarded an Albert Schweitzer Fellowship. He completed his residency training in Psychiatry at the UVMMC and served as Chief Resident during his final year. He was recognized as the UVMMC Resident of Year and received the Arnold P. Gold Award for Humanism and Excellence in Clinical Teaching. He completed Fellowship training in Addiction Psychiatry at the Massachusetts General Hospital and Harvard Medical School.
Dr. Maruti’s clinical focus is on working with acutely ill patients and those with co-occurring disorders. His research interests are in the areas of risk assessment and quality improvement. He has worked with national experts on the revision of the national buprenorphine waiver course. He is the Course Director for the American Academy of Addiction Psychiatry (AAAP) annual Addictions and Their Treatment Course. Additionally, he serves on the Board of Directors of the AAAP.

Derek Blevins - Co-Director

Columbia University Irving Medical Center

Derek Blevins, MD, is an Assistant Professor at Columbia University and a Research Psychiatrist for the Division on Substance Use Disorders at the New York State Psychiatric Institute. He also has a small private practice in Manhattan. He completed his psychiatry residency at the University of Virginia and addiction psychiatry clinical and research fellowship at Columbia University. His research interests include the use of transcranial magnetic stimulation for substance use disorders and comorbid conditions.

Stephanie Hrisko - Co-Director

Morris Village Treatment Center

Dr. Hrisko completed her addiction psychiatry fellowship at the Medical University of South Carolina in 2020 after which she joined the SC Department of Mental Health as a psychiatrist at Morris Village Treatment Center in Columbia, SC. She completed her general psychiatry residency and geriatric psychiatry fellowship at Palmetto Health USC. She earned her MD from the University of South Carolina School of Medicine. She is a former AAAP Travel Award Recipient and American Association for Geriatric Psychiatry Honors Scholar. Her research focus has been on substance use disorders in older adults during residency and fellowship.

Bryon Adinoff - Speaker

University of Colorado School of Medicine

Dr. Adinoff is a Clinical Professor at the University of Colorado School of Medicine. He received his medical degree from Michigan State University, completed residency training in psychiatry at Tulane University, and did a postdoctoral fellowship in the Laboratory of Clinical Studies at the National Institute on Alcohol Abuse and Alcoholism. He recently retired from his position as Distinguished Professor of Alcohol and Drug Abuse Research in the Department of Psychiatry at the University of Texas Southwestern Medical Center and as a psychiatrist for 30 years with the Veterans Affairs. He has published over 160 articles and chapters on the biology and treatment of addiction and is Editor-in-Chief of The American Journal of Drug and Alcohol Abuse. Dr. Adinoff’s work has been funded by the Department of Veterans Affairs, the National Institutes on Drug Abuse (NIDA), and Alcohol Abuse and Alcoholism (NIAAA). He has been recognized as a Distinguished Fellow in the American Academy of Addiction Psychiatry and is a Fellow in the American College of Neuropsychopharmacology. In his semi-retired status, his focus has evolved from studying the consequences of substance use itself to the consequences of the drug war. As a Founding Member and Executive Vice President of Doctors for Cannabis Regulation, he is working to ensure that the harsh, punitive prohibition of cannabis use is replaced by a regulatory system that promotes public health and social justice.

Steven Batki - Speaker

University of California, San Francisco and San Francisco VA Medical Center

Dr. Batki is Professor of Psychiatry at the University of California, San Francisco (UCSF) School of Medicine, and Chief of the Addiction Recovery Treatment Services at the San Francisco Veterans Affairs Health Care System, where he also directs the Addiction Research Program. Dr. Batki is immediate past Director, and current Senior Consultant to the UCSF Addiction Psychiatry Fellowship Program. He is board-certified in psychiatry, addiction psychiatry, and addiction medicine, and is a Distinguished Life Fellow of the American Psychiatric Association, and a Fellow of the American Society of Addiction Medicine. Prior to his current position, Dr. Batki was Director of the Division of Substance Abuse at San Francisco General Hospital from 1983 to 1999, and from 1999 to 2007 served as Professor and Director of Psychiatry Research at the State University of New York (SUNY) Upstate Medical University. Dr. Batki chaired the SAMSHA CSAT Treatment Improvement Protocol No. 37 - Substance Abuse Treatment for Persons with HIV/AIDS, and Treatment Improvement Protocol No. 43 - Medication-Assisted Treatment for Opioid Dependence. Dr. Batki is engaged in addiction research, training, and clinical services. His research focuses on the pharmacological and cognitive treatment of alcohol, opioid and stimulant dependence and co-occurring psychiatric and medical disorders. He has been the recipient of research funding from NIDA, NIAAA, and Department of Defense. Dr. Batki’s current DoD- and NIDA-funded research examines the pharmacotherapy of alcohol use disorders in veterans with co-occurring traumatic brain injury and PTSD, as well as the pharmacotherapy of methamphetamine use disorder. His research group is also exploring neurocognitive training methods in the treatment of substance use disorders.

Kathleen Brady - Speaker

MD, PhD

Medical University of South Carolina, South Carolina Clinical & Translational Research Institute

Dr. Brady is an experienced clinical and translational researcher and has been conducting scientific investigations and clinical work in the field of addictions and psychiatric disorders for over 30 years. Her research focuses on pharmacotherapy of substance use disorders, comorbidity of psychiatric disorders and addictions (e.g., posttraumatic stress disorder and bipolar disorder), gender differences and women’s issues in addictions, and the neurobiologic connections between stress and addictions. She has received numerous federal research grants and has published over 300 peer-reviewed journal articles and co-edited 10 books. She is the principal Investigator of MUSC’s Clinical and Translational Science Award (CTSA), Principal Investigator of the Southern Consortium Node of the NIDA-funded Clinical Trials Network and Director of MUSC’s Women’s Research Center. Her dedication to furthering research careers has attracted a number of junior investigators and clinicians. She has mentored over 25 individual NIH funded faculty development awards (K-awards) and is presently involved in three institutional faculty development programs (CTSA KL2; BIRCWH, NIDA K-12). She has been the Co-Director of MUSC’s NIH- funded post-doctoral fellowship program focused on translational research training in addictions for 15 years.

Roger Chou - Speaker

Oregon Health & Science University

Roger Chou, MD, is Professor of Medicine and Medical Informatics and Clinical Epidemiology, OHSU, and the Pacific Northwest EPC Director. Dr. Chou’s is trained in internal medicine and is internationally recognized as an expert in opioids and pain. Dr. Chou has led over 70 systematic reviews, including numerous review on pain, opioids, overdose prevention, and addiction. Dr. Chou has also conducted primary research on opioids. His reviews were used to develop the 2016 CDC opioid guideline and other high-impact guidelines in this area. He served on the Steering Committee for the 2016 CDC guideline, an NIH-convened research task force for low back pain, an NIH work group to inform the Federal Pain Research Strategy, a federal interagency work group on reducing adverse events associated with opioids, and a CDC opioid prescribing estimates workgroup. He served on a National Academies of Science, Engineering and Medicine committee on Evidence-based Clinical Practice Guidelines for Prescribing Opioids for Acute Pain, serves on the National Academy of Medicine Action Collaborative on Countering the U.S. Opioid Epidemic, was Coordinating Editor of the Cochrane Back and Neck Group and is now a Senior Editor of the Cochrane Musculoskeletal Group, and is on the Board of Scientific Counselors for the CDC’s National Center for Injury Prevention and Control.

Timothy Fong - Speaker

Semel Institute for Neuroscience and Human Behavior at UCLA

Dr. Fong is a Professor of Addiction Psychiatry at the Semel Institute for Neuroscience and Human Behavior at UCLA. He is the director of the UCLA Addiction Psychiatry Fellowship, a one-year program that provides clinical training in the management of addictive disorders. He is also the co-director of the UCLA Gambling Studies Program. The purpose of this program is to examine the underlying causes and clinical characteristics of gambling disorder in order to develop effective, evidence-based treatment strategies. Dr. Fong is Director of the Steering Committee to the UCLA Cannabis Research Initiative, a multidisciplinary effort to examine the full impact of cannabis on the body, mind and brain. Finally, he is the Director of the UCLA Sports Psychiatry Service, a multidisciplinary treatment program that manages the psychiatric needs of UCLA student athletes and professional athletes.

Scope of Work
1. Creating and delivering continuing education programs for sober and mental health companions
2. Determining best practices for sober and mental health companions

Ayana Jordan - Speaker

MD, PhD

Yale University

As an undergraduate, Dr. Jordan attended Hampton University, a historically Black university, where she became interested in basic science. After college, Dr. Jordan conducted HIV research at the National Institutes of Health, where she contemplated combining her love for basic science with the clinical sciences. In 2003, Dr. Jordan began an MD, PhD program at Albert Einstein College of Medicine of Yeshiva University in New York City. In medical school, Dr. Jordan became passionate about serving minority populations, specifically within psychiatry. She completed a general adult psychiatric residency at Yale University in 2015, where she served as Program-Wide Chief. During residency, Dr. Jordan became interested in treating patients with substance use disorders, given the intense stigma witnessed from other disciplines. As such, Dr. Jordan completed specialized training in Addiction Psychiatry at Yale. Dr. Jordan is currently an assistant professor at Yale and an attending physician at Connecticut Mental Health Center. She is committed to increasing access to addiction services within minority communities, both nationally and abroad. Dr. Jordan has done research in Sierra Leone, West Africa examining the link between, mental illness, substance use and stigma, and has served as an expert witness discussing the current mental health system in Sierra Leone. Locally, Dr. Jordan is working on a project to provide a computer based cognitive behavioral therapy program (CBT4CBT) within the Black Church, an evidenced based therapeutic modality shown to be effective in decreasing substance use. Dr. Jordan is interested in making connections with key stakeholders in the Black community to make this project a success. Most recently, Dr. Jordan was appointed the Associate Program Director of Yale's Psychiatry Residency Program. Dr. Jordan is the proud recipient of various clinical and research awards and was recently inducted into the Top 40 under 40 society, by her undergraduate alma mater.

Petros Levounis - Speaker

MD, MA

Rutgers New Jersey Medical School

Dr. Levounis serves as Professor and Chair of the Department of Psychiatry at Rutgers New Jersey Medical School and Chief of Service at University Hospital in Newark, New Jersey. Prior to Rutgers, Dr. Levounis was on the faculty of New York University and Columbia University, where he served as Director of the Addiction Institute of New York and Chief of Addiction Psychiatry at St. Luke’s and Roosevelt Hospitals from 2002 to 2013. He is a Phi Beta Kappa graduate of Stanford University where he studied Chemistry and Biophysics as a combined BS/MS student, before receiving his medical education at Stanford University School of Medicine and the Medical College of Pennsylvania. During medical school, he researched the effects of social class on patient-physician relationships in Oxford, England, and received an MA degree in Sociology from Stanford. Dr. Levounis graduated from the Columbia University residency training program earning the National Institute of Mental Health Outstanding Resident Award and went on to complete his fellowship in Addiction Psychiatry at New York University.

Dr. Levounis has published numerous articles, monographs, and book chapters; has lectured extensively on addiction topics throughout the United States and abroad; has been interviewed by all the major TV networks; and has authored and edited several books including:

• Sober Siblings: How to Help Your Alcoholic Brother or Sister—and Not Lose Yourself
• Substance Dependence and Co-Occurring Psychiatric Disorders
• Handbook of Motivation and Change: A Practical Guide for Clinicians
• The LGBT Casebook
• The Addiction Casebook
• Mastering the New Psychiatric Diagnoses
• The Behavioral Addictions
• Pocket Guide to Addiction Assessment and Treatment
• Becoming Mindful: Integrating Mindfulness into Your Psychiatric Practice
• Motivational Interviewing for Clinical Practice
• Ward Wisdom
• Office-Based Buprenorphine Treatment of Opioid Dependence, 2nd edition
• Pocket Guide to LGBTQ Mental Health: Understanding the Spectrum of Gender and Sexuality

Michelle Lofwall - Speaker

University of Kentucky College of Medicine

Michelle Lofwall, M.D. is a Professor of Behavioral Science & Psychiatry and the Bell Alcohol and Addictions Chair at the University of Kentucky (UK) in the Center on Drug and Alcohol Research. She completed psychiatry residency and a post-doctoral fellowship in behavioral pharmacology at Johns Hopkins University. Dr. Lofwall is the medical director of an active outpatient clinic treating persons with substance use disorders (SUDs) and other psychiatric illnesses. She teaches medical students, physicians, and other allied health professionals about SUDs and mentors students and faculty in SUD research and treatment. She was an expert panelist on SAMHSA’s Medications Treatment of Opioid Use Disorder Treatment Improvement Protocol (TIP) 63. Her clinical research has been funded by NIDA and industry and has focused on medication development for opioid use disorder, evaluation of abuse liability of commonly prescribed psychoactive medications, needs of special populations (e.g., those with complications of IVDU such as endocarditis, pregnant women), and improving the understanding and need for therapeutic response to buprenorphine diversion. She is a past editor of the American Academy of Addiction Psychiatry (AAAP) newsletter, co-director of AAAP’s Addiction and Their Treatment course, board member of the American Society of Addiction Medicine (ASAM), and President of the Kentucky Chapter of the American Society of Addiction Medicine. She currently is a mentor and buprenorphine waiver trainer for the Physician Clinical Support System Mentor for Medication-assisted Treatment (PCSS-MAT) and is involved in more than 10 active research protocols including the NIDA/SAMHSA funded HEALing (Helping End Addiction Long-term) Communities Study.

Carla Marienfeld - Speaker

University of California, San Diego

Carla Marienfeld, MD, is a board-certified addiction psychiatrist and Clinical Professor at the University of California, San Diego who supports recovery in an evidence based, harm-reduction approach through therapy, motivational interviewing, and medication treatment. Her research looks at health outcomes for individuals with substance use disorders, and she edited two books: Motivational Interviewing for Clinical Practice and Absolute Addiction Psychiatry Review: An essential board exam study guide. She has been highly involved in education of colleagues and trainees about addiction psychiatry and effective interventions including buprenorphine treatment and motivational interviewing, and she is the fellowship director for the UCSD Addiction Psychiatry Fellowship. Dr. Marienfeld completed a fellowship in addiction psychiatry and residency training in psychiatry at Yale. During her residency, she was chief resident of psychiatry and founded (and later led) the Yale Global Mental Health Program. She earned a medical degree with honors from Baylor College of Medicine in Houston.

Edward Nunes - Speaker

Columbia University Medical Center

Dr. Nunes is Professor of Psychiatry at Columbia University Medical Center and the New York State Psychiatric Institute (NYSPI), where he has spent his career conducting research on the development of behavioral and pharmacological treatments for patients with alcohol and drug use disorders and the evaluation and treatment of co-occurring psychiatric disorders among patients with substance use disorders. He has published over 200 peer-reviewed articles in addition to various chapters, and one book on the clinical approach to co-occurring psychiatric and substance use disorders. He received his BA from Dartmouth College in 1977, his MD from University of Connecticut in 1981, completed residency training in Psychiatry (1985) and a postdoctoral fellowship in clinical psychopharmacology research (1988) at Columbia University. Dr. Nunes has been a Principal Investigator since 2000 in the NIDA Clinical Trials Network (Greater New York Node), through which he has focused on the translation and dissemination of evidence-based treatments and the design of treatment research in community-based treatment settings. He is extensively involved in mentoring young investigators, particularly physicians and other clinicians, towards careers in research on substance use disorders. He currently serves NIDA on the National Advisory Council on Drug Abuse, and Co-Chairs the New York State Psychiatric Institute IRB. He is a long-time member of the AAAP Scientific Program Committee.

John Renner Jr. - Speaker

Boston University

Dr. Renner is Professor of Psychiatry, Boston University School of Medicine, and Associate Chief of Psychiatry for the VA Boston Healthcare System. He graduated from Yale University and Case University School of Medicine and completed his psychiatric residency at the Tufts- New England Medical Center. In 1969, Dr. Renner served as a psychiatrist with the US Navy in Vietnam, and since 1979 he has been working at the Boston VA where he currently directs its outpatient addiction treatment program. In addition to his clinical activities at the VA, he is Associate Director of the Boston University Medical Center General Psychiatry Residency Program and Director of their Addiction Psychiatry Residency.

Dr. Renner has written and lectured extensively on the treatment of alcoholism and drug addiction. He is a member and former chair of the American Psychiatric Association Council on Addiction Psychiatry, former chair of the APA Council on Adult Psychiatry and former Chair of the APA Expert Advisory Panel on Addiction Psychiatry. In 2018, Dr. Renner co-edited the 2nd edition of the APA Handbook of Office-Based Buprenorphine Treatment for Opioid Use Disorder. He is Past-President of the Board of Directors of the American Academy of Addiction Psychiatry, and a member of the Data Safety Monitoring Board for the Clinical Trials Network of the National Institute on Drug Abuse, a member of the Clinical Advisory Committee of the Physician Health Service of the Massachusetts Medical Society, a Consultant to the Department of Psychiatry, Massachusetts General Hospital, and a member of the faculty of the Harvard Medical School Division on Addictions.

Richard Ries - Speaker

University of Washington School of Medicine

Dr. Ries is Professor of Psychiatry at the University of Washington School of Medicine, in Seattle, Washington. He is board certified in General Psychiatry and in Addiction Psychiatry by the American Board of Psychiatry and Neurology and certified in Addiction Medicine by the American Board of Addiction Medicine. Dr. Ries is Director of the Addictions Programs at Harborview Medical Center in downtown Seattle and Director of the Division of Addictions for the Department of Psychiatry. He was chosen to chair the first national consensus Treatment Improvement Protocol (TIP#9) and TIP #42 on assessment and treatment of persons with co-occurring addiction and mental disorders by the Center for Substance Abuse Treatment. Dr Ries was senior editor of the Key reference text ASAM’s Principles of Addiction Medicine editions 4 and 5. He is currently working on several NIDA, NIAAA, and DOD sponsored grants in the area of addictions treatment and addiction and suicide. His CV includes more than 150 published papers in peer reviewed journals.

Kevin Sevarino - Speaker

MD, PhD

Yale University School of Medicine

Dr. Sevarino trained in psychiatry in the dual clinical/basic research tract at the Yale University School of Medicine. For six years thereafter, he was PI on NIH grants examining neurobiological mechanisms underlying cocaine dependence, and since then has transitioned to being a clinician-educator who remained active in clinical research as a member of the MIRECC VA Team in studies examining new treatments for substance use disorders. He was Medical Director of the Newington Mental Health Care Firm, Connecticut VA Healthcare System from Dec. 2004 through Aug. 2017. He is consulting psychiatrist to Gaylord Hospital, Wallingford, a position he previously held from 1999 - 2009. His particular expertise is in treatment of the dually-diagnosed and non-opiate pharmacological management of chronic pain. He is Associate Clinical Professor of Psychiatry, Yale University School of Medicine. He was subspecialty certified in Psychosomatic Medicine by the American Board of Psychiatry and Neurology from 2009 - 2019, in Addiction Medicine by the American Board of Addiction Medicine from 2010 - 2020, and currently in Addiction Medicine by the American Board of Preventative Medicine. Dr. Sevarino is President of the American Academy of Addiction Psychiatry (AAAP). He was Course Director for the AAAP Board Review Course in Addictions, which developed into the Addictions and Their Treatment Course, from 2007 - 2015. He currently co-directs AAAP’s Advanced Addiction Psychopharmacology course.

Louis Trevisan - Speaker

Yale University School of Medicine

Dr. Trevisan (Associate Professor of Psychiatry) received his MD from Oregon Health Sciences University in 1989. He completed his Psychiatry Residency at Yale University School of Medicine, and he is board certified in Addiction Psychiatry and General Psychiatry. Dr. Trevisan has been a member of the Department of Psychiatry Faculty at Yale School of Medicine and the VA Connecticut Healthcare System for 28 years. Dr. Trevisan teaches in the Addiction Psychiatry and Geriatric Psychiatry Fellowship programs as well as the Psychiatry Residency Program at Yale University. His interests are in aging and substance use disorders, mechanisms of alcohol intoxication and detoxification. Dr. Trevisan is a 2012 recipient of the Nancy C. A. Roeske, MD award for excellence in Medical School Education. He served as the VISN 1 Mental Health Service Line Director for 2 years and recently served as the Tele-SUD Lead Consultant for the VA National Tele-Mental Health Center based at the VA Connecticut in West Haven. He served as the Director of Center for Substance Abuse Treatment at SAMHSA from July 2019 to January 2020. Dr. Trevisan is currently retired from Federal Service but remains active in the Yale Department of Psychiatry and VA Connecticut both clinically and as part of their Psychiatry research endeavors.

Laurence Westreich - Speaker

New York University School of Medicine

Dr. Westreich is a board-certified addiction psychiatrist who specializes in the forensic evaluation of addicted persons. After graduating from Northwestern University with a degree in English Literature, he received his medical degree from the University of Minnesota School Of Medicine. Following an internship in Internal Medicine at the Hennepin County Medical Center in Minneapolis, Minnesota, Dr. Westreich completed a residency in General Psychiatry at New York’s Beth Israel Medical Center, and a fellowship in Addiction Psychiatry at the New York University School of Medicine/Bellevue Hospital. He is board certified by the American Board of Psychiatry and Neurology in general psychiatry, addiction psychiatry, and forensic psychiatry. Dr. Westreich is Associate Professor of Clinical Psychiatry in the Division of Alcoholism and Drug Abuse, Department of Psychiatry, New York University School of Medicine and serves as Consultant on Behavioral Health and Addiction to the Commissioner of Major League Baseball. He is licensed as a Medical Review Officer (M.R.O.), and is the author of Helping the Addict You Love (Simon and Schuster), and A Parents Guide to Teen Addiction (Skyhorse Publishing.)

Jill Williams - Speaker

Rutgers- Robert Wood Johnson Medical School

Jill M. Williams, MD, is Professor of Psychiatry and Director of the Division of Addiction Psychiatry at the Rutgers University-Robert Wood Johnson Medical School in New Brunswick. She also holds faculty appointments at the Cancer Institute of New Jersey and the Rutgers Center for Alcohol Studies. The focus of Dr. Williams work has been in addressing tobacco in individuals with mental illness or other addictions through treatment and systems interventions. Dr Williams has developed training curricula for behavioral health professionals and manualized treatments for treating tobacco in mental health settings. She is a Board Certified Addiction Psychiatry and member of the APA Council on Addictions. Dr. Williams has received research funding from sources including the National Institutes on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), and American Legacy Foundation. Her publications have appeared in numerous journals including Nicotine and Tobacco Research, the Journal of the American Medical Association, and the Journal of Substance Abuse Treatment and in 2015 she was the recipient of the Remarkable Achievement Award of the NJ Psychiatric Association.

Amy Yule - Speaker

Boston Medical Center

Dr. Amy Yule is board certified in adult, child, and addiction psychiatry. She is the Director of Adolescent Addiction Psychiatry at Boston Medical Center and an Assistant Professor at the Boston University School of Medicine. Her research interests include risk factors associated with the development of a substance use disorder in adolescents with psychiatric illness, risky behaviors in adolescent substance users, and treatment of substance use disorders when co-occurring with psychiatric illness. She has NIH funding to evaluate the impact of treating psychopathology in young people on subsequent development of a substance use disorder, and medication treatment for youth with substance use disorders co-occurring with bipolar disorder.

Summary


Availability:	On-Demand


Cost:	Member: $150.00 Non-Member: $200.00


Credit Offered:	No Credit Offered

Create Account

Contains (108)

Dr_ Jordan Answering Participant Questions

Dr_ Ries Answering Participant Questions

Emerging Drugs PDF

General Concepts and Epidemiology PDF

Neurobiology and Genetics PDF

Co-Morbidity of Substance and other Psychiatric Disorders PDF

Psychosocial Treatment of the Addictions PDF

Motivational Interviewing PDF

Substance Use Disorders in Older Population PDF

Urine Drug Testing PDF

Review of Opioids and Treatment of Opioid Use Disorders PDF

Pain and Addiction PDF

Sex and Drugs: Gender Differences in Substance Use Disorders PDF

Tobacco PDF

Pregnancy and Substance Use Disorders PDF

Suicide and Substance Use Disorders PDF

Cannabis PDF

Youth with Substance Use Disorders and Attention Deficit Hyperactivity Disorder PDF

Naloxone Overdose Training PDF

Forensics Issues in Addiction PDF

Stimulant-Related Disorders PDF

Medical Comorbidities in Patients with Substance Use Disorders PDF

Alcohol PDF

Behavioral Addictions PDF

Substance Use Disorders in the Hospital Setting PDF

Q & A Session Recording_ Session 15

Q & A Session Recording_ Session 17

Q & A Session Recording_ Session 18

Q & A Session Recording_ Session 20

Description

Q & A Session Recording

Description

Alcohol

Emerging Drugs

Naloxone Overdose Training

Cannabis

Pregnancy and Substance Use Disorders

Substance Use Disorder in the Hospital Setting

Forensic Issues in Addiction

Motivational Interviewing

Suicide and Substance Use Disorders

Benzodiazepines: The Hidden Epidemic

General Concepts and Epidemiology

Sex and Drugs: Gender Differences in SUDs

Psychosocial Treatment of the Addictions

Urine Drug Testing

Review of Opioids and Treatment of Opioid Use Disorders

Neurobiology and Genetics

Youth with SUDs and Attention Deficit Hyperactivity Disorder

Medical Comorbidities in Patients with Substance Use Disorders

Stimulant-Related Disorders

Behavioral Addictions

Inequities in Addiction Treatment for Racial and Ethnic Minority Populations

Pain and Addiction

Co-Morbidity of Substance and other Psychiatric Disorders

Tobacco

Substance Use Disorders in the Older Population

Emerging Drugs PPT

General Concepts and Epidemiology PPT

Neurobiology and Genetics PPT

Co-Morbidity of Substance and other Psychiatric Disorders PPT

Psychosocial Treatment of the Addictions PPT

Motivational Interviewing PPT

Substance Use Disorders in Older Population PPT

Urine Drug Testing PPT

Review of Opioids and Treatment of Opioid Use Disorders PPt

Pain and Addiction PPT

Sex and Drugs: Gender Differences in Substance Use Disorders PPT

Tobacco PPT

Pregnancy and Substance Use Disorders PPT

Benzodiazepines: The Hidden Epidemic PDF

Suicide and Substance Use Disorders PPT

Cannabis PPT

Youth with Substance Use Disorders and Attention Deficit Hyperactivity Disorder PPT

Naloxone Overdose Training PPT

Forensics Issues in Addiction PPT

Stimulant-Related Disorders PPT

Medical Comorbidities in Patients with Substance Use Disorders PPT

Alcohol PPT

Behavioral Addictions PPT

Inequities in Addiction Treatment for Racial and Ethnic Minority Populations PDF

Substance Use Disorders in the Hospital Setting PPT

Benzodiazepines: The Hidden Epidemic PPT

Inequities in Addiction Treatment for Racial and Ethnic Minority Populations PPT

	The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.		400 Massasoit Avenue Suite 108 East Providence, RI 02914 cmecpd@aaap.org Privacy	About Advocacy Membership Fellowship Education and Resources Training Events